Fully Invested in Shared Success

We seek companies/assets with these characteristics:

• Assets in or nearing their final registrational phase, with a high likelihood of regulatory approval and
  successful commercialization.
• These assets may include new developments, label expansions for existing approved molecules,
  those being developed within the target company, or those being considered for acquisition or
  partnership.
• Both biologics and small molecules are suitable.

Biotech companies often partner with Launch Tx to connect with investors who provide non-equity dilutive, non-debt risk capital for registrational development. These partnerships also provide access to strategic guidance and operational resources to reduce risk, enhance development delivery, and improve the probability of approval.

Large biopharma companies often partner with Launch Tx for operational advice and support on clinical trials and connection to investors who provide financing that can improve the companies’ P&Ls by reducing R&D burden, freeing up capital for core development programs, M&A, lifecycle management, geographic expansion, and other purposes.

We identify potential partnership opportunities through direct outreach, advisor networks, investment banks, and also receive considerable inbound interest.

Our comprehensive due diligence process ensures transparency and progress feedback. Here’s a condensed version of a typical timeline:

Month 1: Introduction, initial diligence, and alignment on terms

Month 2: Focused priority diligence, letter of intent with detailed terms and exclusivity

Month 4: Confirmatory diligence, finalizing outstanding reviews, contracting, and deal closure.

Launch Tx evaluates the co-development partner’s clinical development plan to ensure it is in alignment with regulatory feedback and the current competitive landscape. It is our mission to maximize the trial’s appeal and increase the likelihood of technical and regulatory success.

Launch Tx contributes strategic input to the study’s design and execution to ensure its success.

• During our diligence process, we gather “external perspectives” from Key Opinion Leaders (KOLs), Subject Matter Experts (SMEs), and other experts to benefit our co-development partners.

• In our extended diligence, Launch Tx works with the company to ensure the strategy can be operationalized.
• When we select you as an eligible partner, you gain access to a network of experts to drive strategy alignment, validate the clinical development plan, analyze the competitive landscape, and validate commercial forecasts.
• Our team also assesses program feasibility through benchmarking data, milestones, and estimated program costs.

When we decide to enter a partnership, we gather more comprehensive quotes from external service providers and take every step to maximize the asset’s opportunities for success.

 Launch Tx has an established infrastructure which offers flexible collaboration models to fill any gaps and adapt to specific needs.

• Our involvement spans from advisory services to fully customized operational execution. Each partnership is a uniquely tailored program designed to leverage innovative technologies and multiple vendor relationships to relationships to de-risk and accelerate development.
• With extensive experience, we excel at selecting top-tier external service providers across our robust and expansive networks. Our resourcing model disrupts industry standards by minimizing fragmentation, ensuring high-quality focus and delivery.
• We prioritize regulatory submissions and inspection-readiness based on our uncompromising standards for quality and execution.
• Furthermore, we have access to best-in-class commercial terms typically reserved for big pharma.

While success criteria vary by partnership, Launch Tx is keen to ensure timely regulatory submission leading to potential approval; laser-focused preparation for commercialization and/or strategic transaction(s); and economic success share for investors in the event of approval.